The Primary Immune Deficiency (PID) drugs in development market research report provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Primary Immune Deficiency (PID). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued products.
GlobalData tracks 41 drugs in development for Primary Immune Deficiency (PID) by 34 companies/universities/institutes. The top development phase for Primary Immune Deficiency (PID) is phase ii with 13 drugs in that stage. The Primary Immune Deficiency (PID) pipeline has 28 drugs in development by companies and 13 by universities/ institutes. Some of the companies in the Primary Immune Deficiency (PID) pipeline products market are: Takeda Pharmaceutical, Grifols and X4 Pharmaceuticals.
The key targets in the Primary Immune Deficiency (PID) pipeline products market include Adenosine Deaminase, C-X-C Chemokine Receptor Type 4, and Cytokine Receptor Common Subunit Gamma.
The key mechanisms of action in the Primary Immune Deficiency (PID) pipeline product include Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor with two drugs in Pre-Registration. The Primary Immune Deficiency (PID) pipeline products include six routes of administration with the top ROA being Intravenous and 11 key molecule types in the Primary Immune Deficiency (PID) pipeline products market including Gene-Modified Cell Therapy, and Antibody.
Primary Immune Deficiency (PID) overview
Primary immune deficiency (PID) is defined as weakened immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, and digestive problems such as cramping, loss of appetite, nausea, and diarrhea.
For a complete picture of Primary Immune Deficiency (PID)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
